Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Pristauz, G; Bauernhofer, T; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Hochreiner, G; Forsthuber, EP; Fesl, C; Greil, R; LANCET ONCOL. 2011; 12(7): 63-41.

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Bago-Horvath, Z; Rudas, M; Dubsky, P; Jakesz, R; Singer, CF; Kemmerling, R; Greil, R; Jelen, A; Bohm, G; Jasarevic, Z; Haid, A; Gruber, C; Postlberger, S; Filipits, M; Gnant, M CLIN CANCER RES. 2011; 17(24): 7828-7834.

Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

Wöll, E; Greil, R; Eisterer, W; Bechter, O; Fridrik, MA; Grünberger, B; Zabernigg, A; Mayrbäurl, B; Russ, G; Dlaska, M; Obrist, P; Thaler, J; Anticancer Res. 2011; 31(12): 4439-4443.

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

Lin, NU; Eierman, W; Greil, R; Campone, M; Kaufman, B; Steplewski, K; Lane, SR; Zembryki, D; Rubin, SD; Winer, EP; J Neurooncol. 2011; 105(3): 613-620.

Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

Grundbichler, M; Mlineritsch, B; Ressler, S; Moik, M; Kappacher, A; Rosenlechner, S; Greil, R; Oncology. 2011; 80(1-2): 3-41.

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

Fiegl, M; Falkner, F; Steurer, M; Zojer, N; Hopfinger, G; Haslbauer, F; Winder, G; Voskova, D; Andel, J; Lang, A; Brychtova, Y; Mayer, J; Greil, R; Gastl, G; Ann Hematol. 2011; 90(9):1083-1091

Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Pfeiler, G; Königsberg, R; Fesl, C; Mlineritsch, B; Stoeger, H; Singer, CF; Pöstlberger, S; Steger, GG; Seifert, M; Dubsky, P; Taucher, S; Samonigg, H; Bjelic-Radisic, V; Greil, R; Marth, C; Gnant, M; J Clin Oncol. 2011; 29(19): 2653-2659.

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.

Greil, R; Borštnar, S; Petráková, K; Marcou, Y; Pikiel, J; Wojtukiewicz, MZ; Koza, I; Steger, GG; Linn, M; Das Gupta, A; Cwiertka, K; Onkologie. 2011; 34(5): 233-238.

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer, S; Elandt, K; Greil, R; Hottinger, AF; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M; Acta Oncol. 2011; 50(5): 630-635.

Zoledronic acid for adjuvant use in patients with breast cancer.

Ressler, S; Mlineritsch, B; Greil, R; Expert Rev Anticancer Ther. 2011; 11(3): 333-349.